mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

We have previously demonstrated that mTOR inhibitors (MTIs) are active in preclinical models of acute lymphoblastic leukemia (ALL). MTIs may increase degradation of cyclin D1, a protein involved in dihydrofolate reductase (DHFR) synthesis. Because resistance to methotrexate may correlate with high D...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Teachey, David T., Sheen, Cecilia, Hall, Junior, Ryan, Theresa, Brown, Valerie I., Fish, Jonathan, Reid, Gregor S. D., Seif, Alix E., Norris, Robin, Chang, Yueh J., Carroll, Martin, Grupp, Stephan A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2008
Matèries:
Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518903/
https://ncbi.nlm.nih.gov/pubmed/18544682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-137141
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars